Ranibizumab Treatment Outcomes in Phakic versus Pseudophakic Eyes: An Individual Patient Data Analysis of 2 Phase 3 Trials – Corrected Proof
Objective:
To compare visual outcomes in phakic and pseudophakic eyes treated with monthly intravitreal ranibizumab for exudative age-related macular degeneration (AMD).
Design:
Meta-analysis of individual patient data from 2 phase 3 clinical trials of intravitreal ranibizumab in neovascular AMD (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration [ANCHOR], ClinicalTrials.gov number, NCT00061594; and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration [MARINA], ClinicalTrials.gov number NCT00056836).
Participants and Controls:
A total of 1137 patients from 2 phase 3 clinical trials.
Methods:
Phakic and pseudophakic eyes were treated with (Read more...)